Resources from the same session
LBA65 - Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
Presenter: Oliver Sartor
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA66 - UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Arun Azad
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA65 and LBA66
Presenter: Irene Burger
Session: Proffered paper session: GU tumours, prostate
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: GU tumours, prostate
Resources:
Webcast
LBA67 - Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study
Presenter: Neeraj Agarwal
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1596O - Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
Presenter: Emily Grist
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session: GU tumours, prostate
Resources:
Webcast